Recent exceptional positive changes in investment behavior have benefitted iRadimed Corp (NASDAQ: IRMD): its shorter term price trend turned up, the stock’s recent price rise disrupted its longer term downtrend, and the stock rose on very heavy volume.
Recent small positive changes in fundamentals have benefitted iRadimed Corp (NASDAQ: IRMD): significant quarterly earnings acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of D. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, IRMD is expected to continue to be a major Value Builder.
iRadimed has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. iRadimed has a very low Appreciation Score of 10 but a slightly positive Power Rating of 63, resulting in the Negative Value Trend Rating.
Recent Price Action
On 12/15/23, iRadimed Corp (NASDAQ: IRMD) stock rose modestly by 0.3%, closing at $45.68. Moreover, this advance was accompanied by exceptionally high trading volume at 249% of normal. The stock has risen 9.3% during the last week and has been strong relative to the market over the last nine months.
Be the first to comment